Comparing the Efficacy and Safety of Fremanezumab for Chronic Cluster Headache
- Study Title
- A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
- Teva Identifier
- TV48125-CNS-30057 | 2016-003171-21
- ClinicalTrials.gov Identifier
- NCT02964338
- Study Status
- Terminated
- Trial Condition(s)
- Chronic Cluster Headache
- Interventions
- Drug: Fremanezumab | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- January 17, 2017 - July 18, 2018
- Phase
- Phase 3
